SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors

Cancer Research

Volumn 60, Issue 15, 2000, Pages 4152-4160

  Laird, A D ^a   Vajkoczy, P ^a   Shawver, L K ^a   Thurnher, A ^a   Liang, C ^a   Mohammadi, M ^a   Schlessinger, J ^a   Ullrich, A ^a   Hubbard, S R ^a   Blake, R A ^a   Fong, T A T ^a   Strawn, L M ^a   Sun, L ^a   Tang, C ^a   Hawtin, R ^a   Tang, F ^a   Shenoy, N ^a   Hirth, K P ^a   McMahon, G ^a   Cherrington, J M ^a  

^a SUGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 3 [2,4 DIMETHYL 5 (2 OXO DIHYDRO INDOL 3 YLIDENEMETHYL) IH PYRROL 2 YL]PROPIONIC ACID; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER REGRESSION; COMPETITIVE INHIBITION; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MITOGENESIS; MOLECULAR MODEL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

3T3 CELLS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; KINETICS; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-TYROSINE KINASES; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; RECEPTORS, MITOGEN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033883776     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Signaling vascular morphogenesis and maintenance
2. Vessel cooption, regression and regrowth in tumors mediated by angiopoietins and VEGF
3. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
4. Signal transduction by fibroblast growth factor receptors
5. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor α and β subtypes
6. Molecular and biological properties of vascular endothelial growth factor
7. New paradigms for the treatment of cancer: The role of anti-angiogenesis agents
8. Tyrosine kinase inhibitors: From the emergence of targets to their clinical development
9. Biological roles of fibroblast growth factor-2
10. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis
11. Cell density-dependent regulation of basic fibroblast growth factor expression in human renal cell carcinoma cells
12. Basic fibroblast growth factor in human prostate cancer cells
13. Expression of fibroblast growth factor gene family and its receptor gene family in the human upper gastrointestinal tract
14. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas
15. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancer
16. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II. Correlations with proliferation and angiogenesis
17. Microvascular pericytes express platelet-derived growth factor-β receptors in human healing wounds and colorectal adenocarcinoma
18. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro
19. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-I promote rat aortic angiogenesis in vitro
20. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice
21. Indirect angiogenic cytokines upregulate VEGF and bFGF gene-expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only
22. Vascular endothelial growth factor in human glioma cell lines, induced secretion by EGF, PDGF-BB, and bFGF
23. Platelet-derived growth factor receptor-β is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas
24. Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops
25. Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products
26. Stromal expression of platelet-derived growth factor β-receptor and platelet-derived growth factor B-chain in colorectal cancer
27. Polypeptide modulators of prostatic growth and development
28. Expression of c-sis/platelet-derived growth factor B, insulin-like growth factor I, and transforming growth factor α messenger RNAs and their respective receptor messenger RNAs in primary human gastric carcinomas: In vivo studies with in situ hybridization and immunohistochemistry
29. Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer
30. Expression of growth factors and their receptors in human esophageal carcinomas: Regulation of expression by epidermal growth factor and transforming growth factor α
31. Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: Correlation with stage and rate of progression
32. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer
33. Localization of platelet-derived growth factor β receptor expression in the periepithelial stroma of human breast carcinoma
34. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-y1)methylindenyl]indolin-2-ones as inhibitors of VEGF, PDGF, and FGF receptor tyrosine kinases
35. Flk-1 as a target for tumor growth inhibition
36. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
37. Structure of the FGF receptor tyrosine kinase domain reveals a novel auto inhibitory mechanism
38. Processing of X-ray diffraction data collected in oscillation mode
39. Crystallography and NMR system: A new software suite for macromolecular structure determination
40. Improved methods for building protein models in electron density maps and the location of errors in these models
41. Protein kinase catalytic domain sequence database: Identification of conserved features of primary structure and classification of family members
42. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types
43. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
44. Characterization of angiogenesis and microcirculation of high-grade glioma: An intravital multi-fluorescence microscopic approach in the athymic nude mouse
45. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy
46. Protein kinase inhibitors: Structural determinants for target specificity
47. Tyrosine kinases in disease: Overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials
48. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
49. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF
50. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes
51. Tumor induction of VEGF promoter activity in stromal cells